Dmitry Balyasny’s Ultragenyx Pharmaceutical RARE Stock Holding History

Dmitry Balyasny’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-182,100	Closed	-$4.19M	–	3416
2025 Q4	$4.19M	Sell	182,100 -127,900	-41%	-$4.21M	0.01%	1492
2025 Q3	$9.32M	Buy	310,000 +125,000	+68%	+$3.75M	0.01%	1089
2025 Q2	$6.73M	Sell	185,000 -165,000	-47%	-$5.95M	0.01%	1147
2025 Q1	$12.7M	Buy	350,000 +250,000	+250%	+$10.4M	0.02%	787
2024 Q4	$4.21M	Buy	+100,000	New	+$4.96M	0.01%	1362
2022 Q4	–	Sell	-10,000	Closed	-$414K	–	3151
2022 Q3	$414K	Buy	+10,000	New	+$514K	﹤0.01%	2090

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Dmitry Balyasny's RARE Position: Q2 2026 in Review

Dmitry Balyasny sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 384,364 shares — an estimated $8.05M sold.

Dmitry Balyasny first reported a position in RARE in Q2 2015 and held it in 21 quarters. The position peaked at $12M in Q4 2025. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Dmitry Balyasny reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 384,364 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $8.05M.
Dmitry Balyasny first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 21 quarters.
Dmitry Balyasny's Ultragenyx Pharmaceutical position peaked at $12M in Q4 2025.
308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.